Your browser doesn't support javascript.
loading
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Duong, Vu H; Ruppert, Amy S; Mims, Alice S; Borate, Uma; Stein, Eytan M; Baer, Maria R; Stock, Wendy; Kovacsovics, Tibor; Blum, William; Arellano, Martha L; Schiller, Gary J; Olin, Rebecca L; Foran, James M; Litzow, Mark R; Lin, Tara L; Patel, Prapti A; Foster, Matthew C; Redner, Robert L; Al-Mansour, Zeina; Cogle, Christopher R; Swords, Ronan T; Collins, Robert H; Vergilio, Jo-Anne; Heerema, Nyla A; Rosenberg, Leonard; Yocum, Ashley O; Marcus, Sonja; Chen, Timothy; Druggan, Franchesca; Stefanos, Mona; Gana, Theophilus J; Shoben, Abigail B; Druker, Brian J; Burd, Amy; Byrd, John C; Levine, Ross L; Boyiadzis, Michael M.
Afiliação
  • Duong VH; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Ruppert AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Mims AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Borate U; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Stein EM; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Stock W; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
  • Kovacsovics T; Huntsman Cancer Institute, The University of Utah, Salt Lake City, Utah, USA.
  • Blum W; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Arellano ML; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Schiller GJ; David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
  • Olin RL; Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, USA.
  • Foran JM; Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
  • Litzow MR; Departments of Medical Oncology, Hematology, and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Lin TL; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Patel PA; University of Texas Southwestern Medical Center Medical School, Dallas, Texas, USA.
  • Foster MC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Redner RL; Hillman Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Al-Mansour Z; Department of Medicine, University of Florida, Gainesville, Florida, USA.
  • Cogle CR; Department of Medicine, University of Florida, Gainesville, Florida, USA.
  • Swords RT; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Collins RH; University of Texas Southwestern Medical Center Medical School, Dallas, Texas, USA.
  • Vergilio JA; Foundation Medicine, Cambridge, Massachusetts, USA.
  • Heerema NA; Department of Pathology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Rosenberg L; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.
  • Yocum AO; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.
  • Marcus S; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.
  • Chen T; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Druggan F; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Stefanos M; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Gana TJ; Biopharmatech Consulting, Inc., Leesburg, Virginia, USA.
  • Shoben AB; Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, Ohio, USA.
  • Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Burd A; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.
  • Byrd JC; Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
  • Levine RL; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Boyiadzis MM; Hillman Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Cancer ; 129(15): 2308-2320, 2023 08 01.
Article em En | MEDLINE | ID: mdl-37078412
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Proteína Supressora de Tumor p53 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Proteína Supressora de Tumor p53 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article